Sensei Biotherapeutics is reducing its workforce by 65% as it evaluates strategic options in a weak fundraising environment.
1 minute to read
Sensei Biotherapeutics, a cancer-focused biotech with offices in the Seaport, announced this week it will shed about 65% of its staff while evaluating a potential sale.
As of March 14, 2025, the company had 14 full-time employees and one part-time employee. After the layoffs, about five employees will remain to explore strategic alternatives, handle regulatory and financial reporting requirements, and wind down development activities…